Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Uterine leiomyosarcoma: present management.

Robert L Giuntoli1, Robert E Bristow

  • 1The Kelly Gynecologic Oncology Service, Johns Hopkins Medical Institutions, Baltimore, Maryland 21287, USA. rgiunto1@jhmi.edu

Current Opinion in Oncology
|June 10, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Sociodemographic disparities and hospice referral practice patterns among patients with recurrent cervical cancer.

Gynecologic oncology reports·2026
Same author

Identifying and capitalizing on unique molecular alterations of mucinous ovarian carcinoma for the development of novel therapeutic strategies.

Gynecologic oncology reports·2026
Same author

Population-Level Trends in Lifestyle Factors and Early-Onset Breast, Colorectal, and Uterine Cancers.

Cancers·2026
Same author

Incidence of ESR1 gene mutations among patients with endometrioid endometrial cancer.

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society·2025
Same author

Early administration of adjuvant chemotherapy for patients with advanced-stage malignant ovarian germ cell tumors is associated with an overall survival benefit.

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society·2025
Same author

Outcomes of patients with metastatic squamous cell carcinoma of the vulva.

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society·2025

Recent studies advance understanding of uterine leiomyosarcoma (LMS) management. Key findings include diagnostic tools, prognostic indicators, and the limited benefit of adjuvant therapy, paving the way for novel treatments.

Area of Science:

  • Gynecologic Oncology
  • Medical Imaging
  • Molecular Biology

Background:

  • Uterine leiomyosarcoma (LMS) is a rare gynecologic malignancy.
  • Diagnosis can be challenging due to varied presentations.

Purpose of the Study:

  • To review current research impacting the management of uterine LMS.
  • To highlight advancements in diagnosis, prognosis, and treatment.

Main Methods:

  • Review of recent investigations and clinical studies.
  • Analysis of diagnostic imaging techniques, including PET/CT.
  • Evaluation of prognostic factors and risk assessment.

Main Results:

  • Typical LMS symptoms include bleeding, pain, and pelvic mass; atypical signs like hypercalcemia also occur.

Related Experiment Videos

  • PET/CT aids in diagnosis and surveillance.
  • Tumor stage, grade, and a new risk-assessment index are key prognosticators.
  • Ovarian preservation and adjuvant therapy do not significantly improve survival.

    • Conclusions:

    • Recent research has significantly improved the understanding of uterine LMS.
    • Future novel therapies may emerge from deeper insights into LMS molecular biology.